Source: Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Incannex Healthcare (IHL) commences its phase one human clinical trial to assess the safety of IHL-675A soft gel capsules on healthy volunteers
  • The company’s drug has the potential to prevent and treat inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease
  • The aim of the trial is to demonstrate there are no or minimal side effects associated with the combination of Cannabidiol and Hydroxychloroquine
  • If successful, these results will form part of the food and drug administration investigational new drug application
  • Just before the market opens for the day, IHL is trading at 25.5 cents per share

Incannex Healthcare (IHL) has commenced its phase one human clinical trial to assess the safety of IHL-675A soft gel capsules.

The treatment has the potential to be a multi-use drug candidate for the prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease.

A total of 36 healthy volunteers will take part in this trial and they will be evenly divided across the three arms of the trial.

The aim of the trial is to demonstrate there are no or minimal side effects associated with the combination of Cannabidiol (CBD) and Hydroxychloroquine (HCQ).

HCQ is a disease-modifying anti-rheumatic drug that regulates the activity of the immune system. It can modify the underlying disease process, rather than just treating the symptoms.

If successful, these results will form part of the food and drug administration investigational new drug application.

IHL will conduct the study in South Australia at CMAX’s clinical research facility.

The market for treatments for inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel disease is exceeding US$125 billion (around A$169 billion) per annum.

Just before the market opened for the day, IHL was trading at 25.5 cents per share.

IHL by the numbers
More From The Market Herald
Genetic Technologies (ASX:GTG) - CEO, Simon Morriss

" Genetic Technologies (ASX:GTG) expands EasyDNA into Indian and European markets

Genetic Technologies (ASX:GTG) has embarked on a significant expansion of its recently acquired at-home DNA testing…
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…